The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
Open accessAbstract
The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although b - and g -radiation are viewed as having a relative biologic ef fi ciency (RBE) of 1.0, other emerging RPTs, particularly those that use radionuclides that emit a -particles, carry much a higher RBE ( 21 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-780621-1.50005-8 · Cited by 9,077
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-780620-4.50007-0 · Cited by 5,892
Recommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,868
The Stopping and Range of Ions in Matter
Ziegler, J. F., & Biersack, J. P. (1985) · Springer eBooks · doi:10.1007/978-1-4615-8103-1_3 · Cited by 4,360
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
The Stopping and Ranges of Ions in Matter
(1980) · Elsevier eBooks · doi:10.1016/c2013-0-02882-4 · Cited by 3,012
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,228
International Commission on Radiological Protection
(1969) · Radiology · doi:10.1148/93.6.1298 · Cited by 2,148
Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,715
Research works printed but not linked: 32
- 2005, J Nucl Med., 46, 199S
- 1990, Antibody Immunoconjugates Radiopharm., 4, 85
- 1997, Blood., 90, 2245
- 2006, Cancer Biother Radiopharm., 21, 395
- 2006, Cancer Biother Radiopharm., 21, 396
- 2006, J Nucl Med., 47, 1049
- International Commission on Radiological Protection. Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Philadelphia, PA: Elsevier; 2004. ICRP publication 92.
- 1964, Cancer Res., 24, 683
- 1995, J Nucl Med., 36, 259
- 1989, Lancet., 2, 650
- 1997, J Nucl Med., 38, 727
- 2000, J Nucl Med., 41, 941
- 2007, Ann ICRP., 37, 1
- 1994, J Nucl Med., 35, 521
- 1993, J Nucl Med., 34, 1811
- 1988, Cancer Res., 48, 7022
- 1992, J Nucl Med., 33, 2167
- 1994, J Nucl Med., 35, 303
- Fisher DR. The microdosimetry of monoclonal antibodies labeled with alpha emitters. In: Schlafke-Stelson AT, Watson EE, eds. Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:26–36.
- Kellerer AM. Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry. In: Ebert HG, ed. Proceedings of the Second Symposium on Microdosimetry. Brussels, Belgium: Commission of European Communities; 1970:107–134.
- 1997, J Nucl Med., 38, 1923
- 2004, J Nucl Med., 45, 129
- 2001, J Nucl Med., 42, 1216
- 1999, J Nucl Med., 40, 37S
- 1975, J Nucl Med., 16, 248
- 1999, J Nucl Med., 40, 1935
- 2002, J Nucl Med., 43, 97
- 2003, J Nucl Med., 44, 774
- 2005, J Nucl Med., 46, 1171
- 1969, J Nucl Med., 10, 7
- 1999, J Nucl Med., 40, 1947
- Goodhead DT. Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation. Presented at: CERRIE Workshop; July 21–23, 2003; Oxford, U.K.
Cited by
Sorted by citations
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 1,032
Self-citationKratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 418
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 382
Metadata
- Authors
- Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G.
- Affiliations
- Johns Hopkins University (US)
- Loyola University Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- International Atomic Energy Agency (AT)
- Pacific Northwest National Laboratory (US)
- Vanderbilt University (US)
- Rutgers, The State University of New Jersey (US)
- Texas A&M University (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-01-15
- Volume
- 51
- Issue
- 2
- Pages
- 311-328
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC5680544
- OpenAlex
- W2018649196
- Cited by
- 552
- References
- 363
- Citations by year
- 2026: 60 · 2025: 58 · 2024: 50 · 2023: 54 · 2022: 50 · 2021: 50 · 2020: 39 · 2019: 34 · 2018: 44 · 2017: 17 · 2016: 21 · 2015: 10 · 2014: 25 · 2013: 11 · 2012: 16
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (P50AG005136)
- National Cancer Institute (R01CA109234, R41CA117599, P30CA008748)
- National Institute of Biomedical Imaging and Bioengineering (R01EB001994)
- National Center for Research Resources (R43RR015155)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- alpha-emitting radionuclides, targeted alpha therapy, radiation biology, dosimetry, radionuclide conjugation, radiopharmaceuticals, cancer therapy
- MeSH terms
- Alpha Particles, Cell Survival, Clinical Trials as Topic, Dose-Response Relationship, Radiation, Female, Humans, Male, Neoplasms, Neoplasms, Radiation-Induced, Pamphlets, Radiation-Protective Agents, Radiobiology, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Societies, Medical, Cell Death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
